Drug intelligence / Profile preview

JLM002

Development stage: Preclinical
Lead developer: Jecho Biopharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

JLM002 is an investigational biologic candidate developed by Jecho Biopharmaceuticals for the treatment of mycobacterial infections, including tuberculosis and non-tuberculous mycobacteria (NTM). Developed using Jecho's proprietary recombinant protein expression platform, JLM002 is designed to address the therapeutic challenges associated with infections caused by *Mycobacterium* species. The drug is part of Jecho's broader pipeline of recombinant proteins and monoclonal antibodies targeting infectious diseases, respiratory conditions, and immune system deficiencies. It is currently in early-stage development.

Beyond the preview

Go deeper on JLM002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JLM002.

Explore the full profile